Enhancing Safety and Performance: The Role of EU Medical Device Panels

By João L. Carapinha

February 19, 2026

EU Medical Device Panels: Enhancing Safety and Performance Evaluations

EU Medical Device Panels established by the European Medicines Agency (EMA) provide specialized expertise on clinical and performance evaluations for high-risk medical devices and in vitro diagnostics (IVDs) during conformity assessments, as detailed on the EMA’s dedicated webpage. Mandated by EU Regulations 2017/745 on medical devices and 2017/746 on IVDs, these panels deliver opinions to notified bodies, views on IVD performance, and advice to stakeholders like the Medical Device Coordination Group (MDCG), European Commission, manufacturers, and Member States. This framework ensures timely market access to safe, high-performing devices while driving innovation.

High-Risk Device Assessments

The core functions of EU Medical Device Panels includes evaluating high-risk devices, such as Class III implantables or Class IIb devices for medicinal product administration. Panels support rigorous conformity processes by providing evidential standards that elevate safety and performance.

Guidance and Development Strategies

A key strength of EU Medical Device Panels is their proactive role in advising manufacturers on clinical development, investigations, and orphan device designations for unmet needs. They contribute to guidance documents, common specifications, and international standards, with opinions, views, and advice publicly available via EMA repositories.

Panel Structure and Expertise

Organized into 13 thematic groups—like orthopaedics, circulatory systems, neurology, and IVDs—plus a screening panel and coordination committee, these panels ensure unified procedures. The European Commission appoints members with clinical, scientific, and technical expertise; a central list of eligible experts, including CVs and declarations of interest, supports transparency and ad hoc needs.

Expert Operations and Support

The EMA provides administrative, technical, and scientific support under Regulation (EU) 2022/123. Experts—clinicians, biomedical engineers, and researchers with 10+ years in clinical studies, R&D, or safety assessments—serve renewable three-year terms (five for the central list), earning 450 Euros per full day. Requirements include EU/EEA/Turkey citizenship, no current industry ties, and English proficiency. Applications are open until 2 September 2029.

Reference url

Recent Posts

Progress and Challenges in the FDA Accelerated Approval Pathway: A Policy Roadmap for HEOR

By HEOR Staff Writer

April 21, 2026

In this update, we analyze the evolution of the FDA Accelerated Approval Pathway since the 2022 Food and Drug Omnibus Reform Act (FDORA), highlighting measurable improvements, ongoing evidentiary gaps, and policy recommendations critical for health economics and outcomes research (HEOR), pricing,...
Conditional Reimbursement in Chronic Pain Rehabilitation: Navigating Evidence Gaps and Patient Ac...

By João L. Carapinha

April 20, 2026

Healthcare stakeholders were informed in the Netherlands that Chronic Pain Rehabilitation through Interdisciplinary Medical Specialist Rehabilitation (IMSR) will be removed from the Dutch basic health insurance package for most patients. Under the new ruling by Zorginstituut Nederland, chronic pa...
Advancing Psychedelic Therapy Access for Treatment-Resistant Mental Illness
An Executive Order signed by President Donald J. Trump on April 18, 2026, will significantly advance psychedelic therapy access for serious mental illness. By removing regulatory and scheduling barriers, the order directs the FDA to issue Commissioner’s National Priority Vouchers for eligible psy...